TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-κB pathway by TRAF-binding TNFRs
- 11 February 2005
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 102 (8) , 2874-2879
- https://doi.org/10.1073/pnas.0500187102
Abstract
TNF family members and their receptors contribute to increased gene expression for inflammatory processes and intracellular cascades leading to programmed cell death, both via activation of NF-kappaB. TNF receptor (TNFR)-associated factors (TRAFs) are cytoplasmic adaptor proteins binding to various receptors of the TNFR family. In an attempt to delineate the role of individual TRAFs, we compared NF-kappaB activation by CD40(wt) and CD40 mutants with different TRAF recruitment patterns. Recognized only recently, NF-kappaB signaling occurs at least via two different pathways. Each pathway results in nuclear translocation of two different Reldimers, the canonical p50/RelA and the noncanonical p52/RelB. Here, we show that via TRAF6, CD40 mediates only the activation of the canonical NF-kappaB pathway. Via TRAF2/5, CD40 activates both the canonical and the noncanonical NF-kappaB pathways. We observed that TRAF3 specifically blocked the NF-kappaB activation via TRAF2/5. This inhibitory effect of TRAF3 depends on the presence of an intact zinc finger domain. Paradoxically, suppression of TRAF2/5-mediated NF-kappaB activation by TRAF3 resulted in enhanced transcriptional activity of TRAF6-mediated canonical NF-kappaB emanating from CD40. We also observed that 12 TNFR family members (p75TNFR, LTbetaR, RANK, HVEM, CD40, CD30, CD27, 4-1BB, GITR, BCMA, OX40, and TACI) are each capable of activating the alternative NF-kappaB pathway and conclude that TRAF3 serves as a negative regulator of this pathway for all tested receptors.Keywords
This publication has 46 references indexed in Scilit:
- TRAF interactions with raft‐like buoyant complexes, better than TRAF rates of degradation, differentiate signaling by CD40 and EBV latent membrane protein 1International Journal of Cancer, 2004
- Requirement for TRAF3 in Signaling by LMP1 But Not CD40 in B LymphocytesThe Journal of Experimental Medicine, 2004
- Molecular andin silicocharacterization of a promoter module and C/EBP element that mediate LPS‐induced RANTES/CCL5 expression in monocytic cellsThe FASEB Journal, 2001
- Both Amino- and Carboxyl-Terminal Domains of TRAF3 Negatively Regulate NF-κB Activation Induced by OX40 SignalingBiochemical and Biophysical Research Communications, 2000
- Discrete Signaling Regions in the Lymphotoxin-β Receptor for Tumor Necrosis Factor Receptor-associated Factor Binding, Subcellular Localization, and Activation of Cell Death and NF-κB PathwaysJournal of Biological Chemistry, 2000
- Differential Requirements for Tumor Necrosis Factor Receptor-associated Factor Family Proteins in CD40-mediated Induction of NF-κB and Jun N-terminal Kinase ActivationJournal of Biological Chemistry, 1999
- Dominant Negative Mutants of TRAF3 Reveal an Important Role for the Coiled Coil Domains in Cell Death Signaling by the Lymphotoxin-β ReceptorPublished by Elsevier ,1997
- Modulation of Soluble CD40 Ligand Bioactivity with Anti-CD40 AntibodiesHybridoma, 1997
- Identification of TRAF6, a Novel Tumor Necrosis Factor Receptor-associated Factor Protein That Mediates Signaling from an Amino-terminal Domain of the CD40 Cytoplasmic RegionPublished by Elsevier ,1996
- A cytotoxic CD40/p55 tumor necrosis factor receptor hybrid detects CD40 ligand on herpesvirus saimiri‐transformed T cellsEuropean Journal of Immunology, 1995